Systemic lupus erythematosus (SLE) is a devastating autoimmune disease that can result in
substantial morbidity and mortality. Diagnosis and treatment of SLE are clinical challenges …

Type I interferons have been suspected for decades to have a crucial role in the
pathogenesis of systemic lupus erythematosus (SLE). Evidence has now overturned several …

Objective To explore long‐term safety and tolerability of anifrolumab 300 mg compared with
placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of …

Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant
disease, characterized by multiple organ damage, that in its most severe forms can be life …

Systemic lupus erythematosus (SLE) is a chronic multisystem auto-immune disease with
extremely varied clinical manifestations and a complex pathogenesis. New insights in SLE …

Anifrolumab (anifrolumab-fnia; Saphnelo™) is a monoclonal antibody antagonist of the type
1 interferon receptor (IFNAR). It is being developed by AstraZeneca (under license from …

Objectives In patients with systemic lupus erythematosus (SLE), lupus low disease activity
state (LLDAS) attainment is associated with improved outcomes. We investigated LLDAS …

Dysregulated IFN-1 responses play crucial roles in the development of multiple forms of
autoimmunity. Many patients with lupus, systemic sclerosis, Sjogren's syndrome, and …

Systemic lupus erythematosus (SLE) is a severe multisystem autoimmune disease that can
cause injury in almost every body system. While considered a classic example of …

Objectives To systematically review the literature for assay methods that aim to evaluate type
I interferon (IFN-I) pathway activation and to harmonise-related terminology. Methods Three …